AZD5363 + Placebo + Fulvestrant
Phase 1/2Active 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor Positive Breast Cancer
Conditions
Estrogen Receptor Positive Breast Cancer
Trial Timeline
May 7, 2014 → Dec 31, 2025
NCT ID
NCT01992952About AZD5363 + Placebo + Fulvestrant
AZD5363 + Placebo + Fulvestrant is a phase 1/2 stage product being developed by AstraZeneca for Estrogen Receptor Positive Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT01992952. Target conditions include Estrogen Receptor Positive Breast Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Estrogen Receptor Positive Breast Cancer were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01992952 | Phase 1/2 | Active |
Competing Products
20 competing products in Estrogen Receptor Positive Breast Cancer